ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sarge17
|
11K |
5.5M |
8 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
11K
|
5.5M
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
sarge17
|
11K |
5.5M |
2 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
11K
|
5.5M
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Octoberfest
|
|
sarge17
|
2 |
683 |
0 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
2
|
683
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Where’s the Mundipharma replacement?
|
|
sarge17
|
5 |
1.1K |
2 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
5
|
1.1K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Where’s the Mundipharma replacement?
|
|
sarge17
|
5 |
1.1K |
3 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
5
|
1.1K
|
3
|
|
ASX - By Stock
|
SPL |
Where’s the Mundipharma replacement?
|
|
sarge17
|
5 |
1.1K |
3 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
5
|
1.1K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
2 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
17
|
2.9K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
2 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
17
|
2.9K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change of Director's Interest Notice - Dr Russell Basser
|
|
sarge17
|
29 |
5.3K |
1 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
29
|
5.3K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
4 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
17
|
2.9K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
3 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
17
|
2.9K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
2 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
17
|
2.9K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
1 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
17
|
2.9K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Hard workers and Spiders
|
|
sarge17
|
17 |
2.9K |
3 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
17
|
2.9K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change of Director's Interest Notice - Dr Russell Basser
|
|
sarge17
|
29 |
5.3K |
1 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
29
|
5.3K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change of Director's Interest Notice - Dr Russell Basser
|
|
sarge17
|
29 |
5.3K |
3 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
29
|
5.3K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change of Director's Interest Notice - Dr Russell Basser
|
|
sarge17
|
29 |
5.3K |
3 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
29
|
5.3K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
DEP pipeline development
|
|
sarge17
|
2 |
887 |
0 |
14/09/24 |
14/09/24 |
ASX - By Stock
|
2
|
887
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Publication we have all been waiting on
|
|
sarge17
|
19 |
4.5K |
2 |
13/09/24 |
13/09/24 |
ASX - By Stock
|
19
|
4.5K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Publication we have all been waiting on
|
|
sarge17
|
19 |
4.5K |
0 |
13/09/24 |
13/09/24 |
ASX - By Stock
|
19
|
4.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
DEP-Gemcitabine
|
|
sarge17
|
30 |
7.5K |
2 |
13/09/24 |
13/09/24 |
ASX - By Stock
|
30
|
7.5K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma Receives $5.5M R&D Tax Incentive Refund
|
|
sarge17
|
8 |
2.3K |
1 |
12/09/24 |
12/09/24 |
ASX - By Stock
|
8
|
2.3K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Publication we have all been waiting on
|
|
sarge17
|
19 |
4.5K |
1 |
12/09/24 |
12/09/24 |
ASX - By Stock
|
19
|
4.5K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Covid - Vaccine - Viraleze
|
|
sarge17
|
267 |
69K |
1 |
11/09/24 |
11/09/24 |
ASX - By Stock
|
267
|
69K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
DEP-Gemcitabine
|
|
sarge17
|
30 |
7.5K |
0 |
11/09/24 |
11/09/24 |
ASX - By Stock
|
30
|
7.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Annual Report 2024
|
|
sarge17
|
8 |
2.4K |
0 |
11/09/24 |
11/09/24 |
ASX - By Stock
|
8
|
2.4K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
DEP® DOCETAXEL, DEP® CABAZITAXEL, AND DEP® SN38
|
|
sarge17
|
11 |
2.4K |
0 |
10/09/24 |
10/09/24 |
ASX - By Stock
|
11
|
2.4K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
DEP® DOCETAXEL, DEP® CABAZITAXEL, AND DEP® SN38
|
|
sarge17
|
11 |
2.4K |
0 |
10/09/24 |
10/09/24 |
ASX - By Stock
|
11
|
2.4K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
DEP® DOCETAXEL, DEP® CABAZITAXEL, AND DEP® SN38
|
|
sarge17
|
11 |
2.4K |
1 |
10/09/24 |
10/09/24 |
ASX - By Stock
|
11
|
2.4K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
DEP® DOCETAXEL, DEP® CABAZITAXEL, AND DEP® SN38
|
|
sarge17
|
11 |
2.4K |
0 |
10/09/24 |
10/09/24 |
ASX - By Stock
|
11
|
2.4K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
DEP® DOCETAXEL, DEP® CABAZITAXEL, AND DEP® SN38
|
|
sarge17
|
11 |
2.4K |
1 |
10/09/24 |
10/09/24 |
ASX - By Stock
|
11
|
2.4K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma's anticancer therapies
|
|
sarge17
|
6 |
1.2K |
1 |
10/09/24 |
10/09/24 |
ASX - By Stock
|
6
|
1.2K
|
1
|
|
ASX - By Stock
|
SPL |
DEP pipeline development
|
|
sarge17
|
2 |
887 |
3 |
08/09/24 |
08/09/24 |
ASX - By Stock
|
2
|
887
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Multibagger (10x)
|
|
sarge17
|
37 |
11K |
0 |
08/09/24 |
08/09/24 |
ASX - By Stock
|
37
|
11K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Replacement or Expansion
|
|
sarge17
|
34 |
6.8K |
0 |
07/09/24 |
07/09/24 |
ASX - By Stock
|
34
|
6.8K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
2024 Hand Wringing Festival (AGM)
|
|
sarge17
|
7 |
1.7K |
3 |
07/09/24 |
07/09/24 |
ASX - By Stock
|
7
|
1.7K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
2024 Hand Wringing Festival (AGM)
|
|
sarge17
|
7 |
1.7K |
2 |
07/09/24 |
07/09/24 |
ASX - By Stock
|
7
|
1.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
2024 Hand Wringing Festival (AGM)
|
|
sarge17
|
7 |
1.7K |
0 |
07/09/24 |
07/09/24 |
ASX - By Stock
|
7
|
1.7K
|
0
|
|
ASX - By Stock
|
SPL |
2024 Hand Wringing Festival (AGM)
|
|
sarge17
|
7 |
1.7K |
2 |
06/09/24 |
06/09/24 |
ASX - By Stock
|
7
|
1.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
2 |
06/09/24 |
06/09/24 |
ASX - By Stock
|
32
|
5.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Shareholder Update October 2020
|
|
sarge17
|
8 |
3.5K |
0 |
06/09/24 |
06/09/24 |
ASX - By Stock
|
8
|
3.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
0 |
06/09/24 |
06/09/24 |
ASX - By Stock
|
32
|
5.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
0 |
05/09/24 |
05/09/24 |
ASX - By Stock
|
32
|
5.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
0 |
05/09/24 |
05/09/24 |
ASX - By Stock
|
32
|
5.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
1 |
05/09/24 |
05/09/24 |
ASX - By Stock
|
32
|
5.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
1 |
05/09/24 |
05/09/24 |
ASX - By Stock
|
32
|
5.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
1 |
05/09/24 |
05/09/24 |
ASX - By Stock
|
32
|
5.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
0 |
05/09/24 |
05/09/24 |
ASX - By Stock
|
32
|
5.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is a Peer Review required for Viraleze covid viral load claim?
|
|
sarge17
|
32 |
5.2K |
2 |
04/09/24 |
04/09/24 |
ASX - By Stock
|
32
|
5.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in substantial holding
|
|
sarge17
|
17 |
4.0K |
1 |
29/08/24 |
29/08/24 |
ASX - By Stock
|
17
|
4.0K
|
1
|
|